Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 496 participants.
Also called NCT05041010
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 496 participants
- Sponsor
- Registry
-
NCT05041010
-
- Other papers using this trial's data
- Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05041010. Randomized; triple masking; primary purpose treatment. Start 2021-12-25 (actual); primary completion 2024-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
- Acronym
- RODIN
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Neu2000KWL group
- Intervention (Drug)
- Placebo group
- Lead sponsor
- GNT Pharma
Record details
- Record id
cardio:ct-nct05041010- Content hash
2e4cb0b826db3134914671eb36f8b153a8c28e6ed726732c7e80aeb8133eb1b9